ELAHERE- mirvetuximab soravtansine injection, solution

ELAHERE by

Drug Labeling and Warnings

ELAHERE by is a Prescription medication manufactured, distributed, or labeled by ImmunoGen, Inc., BSP Pharmaceuticals S.p.A., AndersonBrecon, Inc. (doing business as PCI Pharma Services), Boehringer Ingelheim Pharma GmbH & Co. KG, Element Materials Technology Pharma US, LLC, Millipore Sigma, Sicor S.r.l, BioReliance Corporation, BioReliance Ltd., Eurofins Biolab S.r.l. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • BOXED WARNING (What is this?)

    WARNING: OCULAR TOXICITY

    • ELAHERE can cause severe ocular toxicities, including visual impairment, keratopathy, dry eye, photophobia, eye pain, and uveitis [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)].
    • Conduct an ophthalmic exam including visual acuity and slit lamp exam prior to initiation of ELAHERE, every other cycle for the first 8 cycles, and as clinically indicated [see Dosage and Administration (2.3)].
    • Administer prophylactic artificial tears and ophthalmic topical steroids [see Dosage and Administration (2.3) and Warnings and Precautions (5.1)].
    • Withhold ELAHERE for ocular toxicities until improvement and resume at the same or reduced dose [see Dosage and Administration (2.4) and Warnings and Precautions (5.1)].
    • Discontinue ELAHERE for Grade 4 ocular toxicities [see Dosage and Administration (2.4) and Warnings and Precautions (5.1)].
  • 1 INDICATIONS AND USAGE

    ELAHERE® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test [see Dosage and Administration (2.1)].

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Patient Selection

    Select patients for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer with ELAHERE based on the presence of FRα tumor expression [see Indications & Usage (1) and Clinical Studies (14)] using an FDA-approved test.

    Information on FDA-approved tests for the measurement of FRα tumor expression is available at http://www.fda.gov/CompanionDiagnostics.

    2.2 Recommended Dosage

    The recommended dosage of ELAHERE is 6 mg/kg adjusted ideal body weight (AIBW) administered once every 3 weeks (21-day cycle) as an intravenous infusion until disease progression or unacceptable toxicity [see Dosage and Administration (2.5)]. Dosing based on AIBW reduces exposure variability for patients who are either under or overweight.

    The total dose of ELAHERE is calculated based on each patient’s AIBW using the following formula:

          AIBW = Ideal Body Weight (IBW [kg]) + 0.4*(Actual weight [kg] – IBW)

          Female IBW [kg] = 0.9*height[cm] – 92

    2.3 Premedication and Required Eye Care

    Premedication 

    Administer the premedications in Table 1 prior to each infusion of ELAHERE to reduce the incidence and severity of infusion related reactions (IRRs), nausea, and vomiting. 

    Table 1: Premedication Prior to Each ELAHERE Infusion
    PremedicationRoute of AdministrationExamples (or equivalent)Administration Time Prior to ELAHERE Infusion
    Corticosteroidintravenousdexamethasone 10 mg
    Antihistamineoral or intravenousdiphenhydramine 25 mg to 50 mgAt least 30 minutes prior
    Antipyreticoral or intravenousacetaminophen 325 mg to 650 mg
    Antiemeticoral or intravenous5-HT3 serotonin receptor antagonist or appropriate alternativesBefore each dose and thereafter as needed

    Consider additional premedications including corticosteroids the day prior to ELAHERE administration for patients who experienced IRRs. 

    Ophthalmic Exams and Premedication

    Ophthalmic Exam: Conduct an ophthalmic exam including visual acuity and slit lamp exam prior to initiation of ELAHERE, every other cycle for the first 8 cycles, and as clinically indicated.

    Ophthalmic Topical Steroids: The use of ophthalmic topical steroids is recommended. The initial prescription and renewals of any corticosteroid medication should be made only after examination with a slit lamp. Administer one drop of ophthalmic topical steroids in each eye 6 times daily starting the day prior to each infusion until day 4; then administer one drop in each eye 4 times daily for days 5-8 of each cycle of ELAHERE [see Warnings and Precautions (5.1)].

    Lubricating Eye Drops: The use of lubricating eye drops at least four times daily and as needed is recommended during treatment with ELAHERE. Instruct patients to use lubricating eye drops and advise to wait at least 10 minutes after ophthalmic topical steroid administration before instilling lubricating eye drops [see Warnings and Precautions (5.1)].

    2.4 Dosage Modifications

    Table 2 provides dose reduction levels and Table 3 provides dosage modifications for ELAHERE due to adverse reactions.

    Table 2: Dosage Reduction Schedule
    ELAHERE Dose Levels
    First Dose Reduction5 mg/kg AIBW once every 3 weeks (21-day cycle)
    Second Dose Reduction4 mg/kg AIBW once every 3 weeks (21-day cycle) *

    * Permanently discontinue in patients who cannot tolerate 4 mg/kg AIBW.

    Table 3: Dosage Modifications for Adverse Reactions
    Adverse ReactionSeverity of Adverse Reaction*Dosage Modification
    Nonconfluent superficial keratitisMonitor.
    Keratitis/Keratopathy
    [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)]    		Confluent superficial keratitis, a cornea epithelial defect, or 3-line or more loss in best corrected visual acuityWithhold until improved or resolved, then maintain at same dose level or consider dose reduction.
    Corneal ulcer or stromal opacity or best corrected distance visual acuity 20/200 or worseWithhold until improved or resolved, then reduce by one dose level.
    Corneal perforation Permanently discontinue.
    Grade 1/ Rare cell in anterior chamberMonitor.
    Uveitis
    [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)]    		Grade 2/ 1-2+ Cell or Flare in anterior chamberWithhold until Grade 1 or less, then maintain dose at same dose level.
    Grade 3/ 3+ Cell or Flare in anterior chamberWithhold until Grade 1 or less, then reduce dose by one dose level.
    Grade 4/ HypopyonPermanently discontinue.
    Grade 1Monitor.
    Pneumonitis
    [see Warnings and Precautions (5.2) and Adverse Reactions (6.1)]    		Grade 2Withhold until Grade 1 or less, then maintain at same dose level or consider dose reduction.
    Grade 3 or 4Permanently discontinue.
    Peripheral Neuropathy
    [see Warnings and Precautions (5.3) and Adverse Reactions (6.1)]    		Grade 2Withhold until Grade 1 or less, then reduce by one dose level.
    Grade 3 or 4Permanently discontinue.
    Grade 1Maintain infusion rate.
    Infusion-Related Reactions/Hypersensitivity
    [see Adverse Reactions (6.1)]    		Grade 2
    • Interrupt infusion and administer supportive treatment.
    • After recovery from symptoms, resume the infusion at 50% of the previous rate, and if no further symptoms appear, increase rate as appropriate until infusion is completed [see Dosage and Administration (2.5)].
    • Administer additional premedication for future cycles [see Dosage and Administration (2.3)].
    Grade 3 or 4
    • Immediately stop infusion and administer supportive treatment.
    • Advise patient to seek emergency treatment and immediately notify their healthcare provider if the infusion-related symptoms recur.
    • Permanently discontinue.
    Hematological
    [see Adverse Reactions (6.1)]    		Grade 3 or 4Withhold until Grade 1 or less, then resume at one lower dose level.
    Other Adverse ReactionsGrade 3Withhold until Grade 1 or less, then resume at one lower dose level.
    [see Adverse Reactions (6.1)]Grade 4Permanently discontinue.

    * Unless otherwise specified, National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.

    2.5 Instructions for Preparation and Administration

    Preparation

    • ELAHERE is a hazardous drug. Follow applicable special handling and disposal procedures1.
    • Calculate the dose (mg) (based on the patient’s AIBW), total volume (mL) of solution required, and the number of vials of ELAHERE needed [see Recommended Dosage (2.2) and Dose Modifications (2.4)]. More than one vial will be needed for a full dose.
    • Remove the vials of ELAHERE from the refrigerator and allow to warm to room temperature.
    • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. ELAHERE is a clear to slightly opalescent, colorless solution.
    • Gently swirl and inspect each vial prior to withdrawing the calculated dose volume of ELAHERE. Do not shake the vial.
    • Using aseptic technique, withdraw the calculated dose volume of ELAHERE for subsequent dilution.
    • ELAHERE contains no preservatives and is intended for single-dose only. Discard any unused drug remaining in the vial.

    Dilution

    • ELAHERE must be diluted prior to administration with 5% Dextrose Injection, USP to a final concentration of 1 mg/mL to 2 mg/mL.
    • ELAHERE is incompatible with 0.9% Sodium Chloride Injection. ELAHERE must not be mixed with any other drugs or intravenous fluids.
    • Determine the volume of 5% Dextrose Injection, USP required to achieve the final diluted drug concentration. Either remove excess 5% Dextrose Injection, USP from a prefilled intravenous bag or add the calculated volume of 5% Dextrose Injection, USP to a sterile empty intravenous bag. Then add the calculated dose volume of ELAHERE to the intravenous bag.
    • Gently mix the diluted drug solution by slowly inverting the bag several times to assure uniform mixing. Do not shake or agitate. 
    • If the diluted infusion solution is not used immediately, store solution either at ambient temperature [(18°C to 25°C (64.4°F to 77°F)] for no more than 8 hours (including infusion time), or under refrigeration at 2°C to 8°C (36°F to 46°F) for no more than 12 hours. If refrigerated, allow the infusion bag to reach room temperature prior to administration. After refrigeration, administer diluted infusion solutions within 8 hours (including infusion time).
    • Do not freeze prepared infusion solution.

    Administration

    • Inspect the ELAHERE intravenous infusion bag visually for particulate matter and discoloration prior to administration.
    • Administer pre-medications prior to ELAHERE administration [see Premedication and Prophylactic Regimen (2.3)].
    • Administer ELAHERE as an intravenous infusion only, using a 0.2 or 0.22 µm polyethersulfone (PES) in-line filter. Do not substitute other membrane materials.
    • Administer the initial dose as an intravenous infusion at the rate of 1 mg/min. If well tolerated after 30 minutes at 1 mg/min, the infusion rate can be increased to 3 mg/min. If well tolerated after 30 minutes at 3 mg/min, the infusion rate can be increased to 5 mg/min.
    • If no infusion-related reactions occur with the previous dose, subsequent infusions should be started at the maximally tolerated rate and may be increased up to a maximum infusion rate of 5 mg/min, as tolerated.
    • Following the infusion, flush the intravenous line with 5% Dextrose Injection, USP to ensure delivery of the full dose. Do not use any other intravenous fluids for flushing.
  • 3 DOSAGE FORMS AND STRENGTHS

    Injection: 100 mg/20 mL (5 mg/mL) clear to slightly opalescent, colorless solution in a single-dose vial.

  • 4 CONTRAINDICATIONS

    None.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Ocular Disorders

    ELAHERE can cause severe ocular adverse reactions, including visual impairment, keratopathy (corneal disorders), dry eye, photophobia, eye pain, and uveitis.

    Ocular adverse reactions occurred in 59% of patients with ovarian cancer treated with ELAHERE. Eleven percent (11%) of patients experienced Grade 3 ocular adverse reactions, including blurred vision, keratopathy (corneal disorders), dry eye, cataract, photophobia, and eye pain; two patients (0.3%) experienced Grade 4 events (keratopathy and cataract). The most common (≥5%) ocular adverse reactions were blurred vision (48%), keratopathy (36%), dry eye (27%), cataract (16%), photophobia (14%), and eye pain (10%). [see Adverse Reactions (6.1)].

    The median time to onset for first ocular adverse reaction was 5.1 weeks (range: 0.1 to 68.6). Of the patients who experienced ocular events, 53% had complete resolution; 38% had partial improvement (defined as a decrease in severity by one or more grades from the worst grade at last follow up. Ocular adverse reactions led to permanent discontinuation of ELAHERE in 1% of patients.

    Premedication and use of lubricating and ophthalmic topical steroid eye drops during treatment with ELAHERE are recommended [see Dosage and Administration (2.3)]. Advise patients to avoid use of contact lenses during treatment with ELAHERE unless directed by a healthcare provider.

    Refer patients to an eye care professional for an ophthalmic exam including visual acuity and slit lamp exam prior to treatment initiation, every other cycle for the first 8 cycles, and as clinically indicated. Promptly refer patients to an eye care professional for any new or worsening ocular signs and symptoms.

    Monitor for ocular toxicity and withhold, reduce, or permanently discontinue ELAHERE based on severity and persistence of ocular adverse reactions. [see Dosage and Administration (2.4)]. 

    5.2 Pneumonitis

    Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ELAHERE.

    Pneumonitis occurred in 10% of patients treated with ELAHERE, including 1% with Grade 3 events and 1 patient (0.1%) with a Grade 4 event. One patient (0.1%) died due to respiratory failure in the setting of pneumonitis and lung metastases. One patient (0.1%) died due to respiratory failure of unknown etiology.

    Pneumonitis led to permanent discontinuation of ELAHERE in 3% of patients.

    Monitor patients for pulmonary signs and symptoms of pneumonitis, which may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams. Infectious, neoplastic, and other causes for such symptoms should be excluded through appropriate investigations. Withhold ELAHERE for patients who develop persistent or recurrent Grade 2 pneumonitis until symptoms resolve to ≤ Grade 1 and consider dose reduction. Permanently discontinue ELAHERE in all patients with Grade 3 or 4 pneumonitis [see Dosage and Administration (2.4)]. Patients who are asymptomatic may continue dosing of ELAHERE with close monitoring.

    5.3 Peripheral Neuropathy

    Peripheral neuropathy occurred in 36% of patients with ovarian cancer treated with ELAHERE across clinical trials; 3% of patients experienced Grade 3 peripheral neuropathy. Peripheral neuropathy adverse reactions included peripheral neuropathy (20%), peripheral sensory neuropathy (9%), paraesthesia (6%), neurotoxicity (3%), hypoaesthesia (1%), peripheral motor neuropathy (0.9%), polyneuropathy (0.3%), and peripheral sensorimotor neuropathy (0.1%).

    The median time to onset of peripheral neuropathy was 5.9 weeks (range 0.1 to 126.7). Of the patients who experienced peripheral neuropathy, 23% had complete resolution and 12% had partial improvement (defined as a decrease in severity by one or more grades from the worst grade) at last follow up. Peripheral neuropathy led to discontinuation of ELAHERE in 0.7% of patients.

    Monitor patients for signs and symptoms of neuropathy, such as paresthesia, tingling or a burning sensation, neuropathic pain, muscle weakness, or dysesthesia. For patients experiencing new or worsening peripheral neuropathy, withhold dosage, dose reduce, or permanently discontinue ELAHERE based on the severity of peripheral neuropathy [see Dosage and Administration (2.4)].

    5.4 Embryo-Fetal Toxicity

    Based on its mechanism of action, ELAHERE can cause embryo-fetal harm when administered to a pregnant woman because it contains a genotoxic compound (DM4) and affects actively dividing cells.

    Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ELAHERE and for 7 months after the last dose [see Use in Specific Populations (8.1, 8.3)].

  • 6 ADVERSE REACTIONS

    The following adverse reactions are discussed elsewhere in the labeling:

    • Ocular Disorders [see Warnings and Precautions (5.1)].
    • Pneumonitis [see Warnings and Precautions (5.2)].
    • Peripheral Neuropathy [see Warnings and Precautions (5.3)].

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    The pooled safety population described in Warnings and Precautions reflect exposure to ELAHERE in 682 patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer at 6 mg/kg AIBW administered intravenously once every 3 weeks until disease progression or unacceptable toxicity in Study 0416, Study 0417, Study 0403 (NCT02631876), and Study 0401 (NCT01609556). The median duration of treatment was 4.4 months (range: 1.0 to 30.0). In the pooled safety population, the most common (≥20%) adverse reactions, including laboratory abnormalities, were increased aspartate aminotransferase, fatigue, increased alanine aminotransferase, blurred vision, nausea, increased alkaline phosphatase, diarrhea, abdominal pain, keratopathy, peripheral neuropathy, musculoskeletal pain, decreased lymphocytes, decreased platelets, decreased magnesium, decreased hemoglobin, dry eye, constipation, decreased leukocytes, vomiting, decreased albumin, decreased appetite, and decreased neutrophils.

    Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Study 0416

    The safety of ELAHERE was evaluated in Study 0416, a multicenter, open-label, active-controlled, randomized, two-arm, study in patients (n=453) with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer [see Clinical Studies (14)]. Patients received ELAHERE 6 mg/kg AIBW once every 3 weeks until disease progression or unacceptable toxicity. The median duration of treatment was 5 months (range: 0.69 to 27.4).

    Serious adverse reactions occurred in 24% of patients treated with ELAHERE. The most common (≥2%) serious adverse reactions were intestinal obstruction (5%), abdominal pain (3%), and pleural effusion (3%). Fatal adverse reactions occurred in 3% of patients, including intestinal obstruction, dyspnea in the setting of subileus, neutropenic sepsis, cardiopulmonary failure, respiratory failure, ischemic stroke, and pulmonary embolus.

    Permanent discontinuation of ELAHERE due to adverse reactions occurred in 9% of patients. The most common (≥1%) adverse reactions leading to permanent discontinuation were pneumonitis (2%), blurred vision (1%), and peripheral neuropathy (1%).

    Dosage delays of ELAHERE due to an adverse reaction occurred in 54% of patients treated with ELAHERE. Adverse reactions which required dosage delays in ≥3% of patients included blurred vision (22%), keratopathy (19%), dry eye (7%), neutropenia (6%), pneumonitis (6%), photophobia (5%), cataract (4%), and peripheral neuropathy (4%).

    Dose reductions of ELAHERE due to an adverse reaction occurred in 34% of patients. Adverse reactions which required dose reductions in ≥3% of patients included blurred vision (14%), keratopathy (10%), peripheral neuropathy (6%), and dry eye (5%).

    Tables 4 and 5 summarize adverse reactions and laboratory abnormalities, respectively, occurring in ≥10% of patients who received ELAHERE in Study 0416.

    Table 4: Adverse Reactions Occurring in ≥10% of Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Received ELAHERE in Study 0416
    Adverse ReactionELAHERE
    (n=218)    		Chemotherapy¥
    (n=207)
    All Grades
    (%)    		Grades 3-4
    (%)    		All Grades
    (%)    		Grades 3-4
    (%)
    Gastrointestinal disorders
    Abdominal pain*343232
    Diarrhea291170.5
    Constipation270191
    Nausea272292
    Vomiting183181
    Eye disorders
    Blurred vision※45930
    Keratopathy†371100
    Dry eye‡29350
    Photophobia180.50.50
    Cataract˄1630.50
    General disorders and administration site conditions
    Fatigue⸙473417
    Nervous system disorders
    Peripheral neuropathy374234
    Headache140100
    Musculoskeletal and connective tissue disorders
    Musculoskeletal pain♦311212
    Metabolism and nutrition disorders
    Decreased appetite181141
    Respiratory, thoracic, and mediastinal disorders
    Pneumonitis± 100.50.50

    ¥ Chemotherapy: paclitaxel, pegylated liposomal doxorubicin (PLD), topotecan.

    ※ Blurred vision includes vision blurred, vitreous floaters, visual acuity reduced, diplopia, accommodation disorder, and visual impairment.

    † Keratopathy includes corneal disorder, corneal epithelial microcysts, keratitis, keratopathy, corneal deposits, punctate keratitis, and corneal opacity.

    ‡ Dry eye includes dry eye and lacrimation increased.

    ˄ Cataract includes cataract and cataract nuclear.

    ⸙ Fatigue includes fatigue and asthenia.

    * Abdominal pain includes abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort.

    Peripheral neuropathy includes neuropathy peripheral, peripheral sensory neuropathy, peripheral motor neuropathy, paresthesia, hypoesthesia, polyneuropathy, neurotoxicity, and peripheral sensorimotor neuropathy.

    ♦ Musculoskeletal pain includes back pain, myalgia, neck pain, arthralgia, musculoskeletal pain, non-cardiac chest pain, bone pain, pain in extremity, musculoskeletal stiffness, musculoskeletal chest pain, and musculoskeletal discomfort.

    ± Pneumonitis includes pneumonitis, interstitial lung disease, respiratory failure, and organizing pneumonia.

    Clinically relevant adverse reactions occurring in <10% of patients who received ELAHERE in Study 0416 included infusion related reactions/hypersensitivity (8%).

    Table 5: Select Laboratory Abnormalities ≥10% for All Grades, in Patients Who Received ELAHERE in Study 0416
    Laboratory AbnormalityELAHERE
    (n=218)    		Chemotherapy
    (n=207)
    All Grades
    %    		Grades 3-4
    %    		All Grades
    %    		Grades 3-4
    %
    Liver Function Tests
    Increased aspartate aminotransferase570140
    Increased alanine aminotransferase381151
    Increased alkaline phosphatase301131
    Chemistry
    Decreased albumin211272
    Decreased magnesium211292
    Decreased sodium160180
    Decreased potassium151111
    Increased calcium12050
    Decreased bicarbonate110110
    Increased creatinine100110
    Hematology*
    Decreased lymphocytes2734211
    Decreased leukocytes2315310
    Decreased neutrophils2214517
    Decreased hemoglobin181638
    Decreased platelets171205

    * The denominator used to calculate the rate varied from 63 to 214 (ELAHERE); 63 to 194 (IC Chemo) based on the number of patients with a baseline value and at least one post-treatment value.

    Study 0417

    The safety of ELAHERE was evaluated in Study 0417, a single-arm, open-label study in patients (n=106) with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer [see Clinical Studies (14)]. Patients received ELAHERE 6 mg/kg AIBW once every 3 weeks until disease progression or unacceptable toxicity. The median duration of treatment was 4.2 months (range: 0.7 to 13.3).

    Serious adverse reactions occurred in 31% of patients treated with ELAHERE. The most common (≥2%) serious adverse reactions were intestinal obstruction (8%), ascites (4%), infection (3%), and pleural effusion (3%). Fatal adverse reactions occurred in 2% of patients, including small intestinal obstruction (1%) and pneumonitis (1%).

    Permanent discontinuation of ELAHERE due to adverse reactions occurred in 11% of patients. The most common (≥2%) adverse reactions leading to permanent discontinuation were intestinal obstruction (2%) and thrombocytopenia (2%). One patient (0.9%) permanently discontinued ELAHERE due to visual impairment (unilateral decrease to BCVA < 20/200 that resolved to baseline after discontinuation).

    Dosage delays of ELAHERE due to an adverse reaction occurred in 39% of patients treated with ELAHERE. Adverse reactions which required dosage delays in ≥3% of patients included blurred vision (15%), keratopathy (11%), neutropenia (6%), dry eye (5%), cataracts (3%), and increased gamma-glutamyltransferase (3%).

    Dose reductions of ELAHERE due to an adverse reaction occurred in 20% of patients. Adverse reactions which required dose reductions in ≥3% of patients included blurred vision (9%) and keratopathy (7%).

    Table 6 summarizes the adverse reactions (≥10%) in patients treated with ELAHERE in Study 0417.

    Table 6: Adverse Reactions (≥10%) in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Received ELAHERE in Study 0417
    Adverse ReactionAll Grades
    N=106
    (%)    		Grade 3-4
    N=106
    (%)
    Eye disorders
    Blurred Vision※507
    Keratopathy†379
    Dry eye‡272
    Cataract183
    Photophobia170
    Eye pain§100
    General disorders
    Fatigue493
    Gastrointestinal disorders
    Nausea400
    Abdominal pain*367
    Diarrhea313
    Constipation301
    Vomiting190
    Abdominal distension 110
    Nervous system disorders
    Peripheral neuropathy332
    Metabolism and nutrition disorders
    Decreased appetite181
    Musculoskeletal and connective tissue disorders
    Arthralgia170
    Myalgia100
    Respiratory, thoracic, and mediastinal disorders
    Dyspnea^120

    ※ Blurred vision includes vision blurred, vitreous floaters, visual acuity reduced, diplopia, presbyopia, accommodation disorder, visual impairment, and refraction disorder.

    † Keratopathy includes corneal disorder, corneal epithelial microcysts, corneal epithelial defect, keratitis, keratopathy, corneal deposits, and punctate keratitis.

    ‡ Dry eye includes dry eye and lacrimation increased.

    § Eye pain includes eye pain and ocular discomfort.

    ⸙ Fatigue includes fatigue and asthenia.

    * Abdominal pain includes abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort.

    Peripheral neuropathy includes neuropathy peripheral, peripheral sensory neuropathy, peripheral motor neuropathy, paresthesia, hypoesthesia, polyneuropathy, and neurotoxicity.

    ^ Dyspnea includes dyspnea and exertional dyspnea.

    Clinically relevant adverse reactions occurring in <10% of patients who received ELAHERE in Study 0417 included infusion related reactions/hypersensitivity (9%), pneumonitis (8%), and uveitis (1%).

    Table 7 summarizes the laboratory abnormalities in Study 0417.

    Table 7: Select Laboratory Abnormalities ≥10% for All Grades, or ≥2% for Grades 3-4 in Patients Who Received ELAHERE
    Laboratory AbnormalityELAHERE*
    All Grades
    (%)    		Grade 3-4
    (%)
    Liver Function Tests
    Increased aspartate aminotransferase502
    Increased alanine aminotransferase392
    Increased alkaline phosphatase301
    Hematology*
    Decreased lymphocytes357
    Decreased leukocytes261
    Decreased neutrophils263
    Decreased hemoglobin253
    Decreased platelets182
    Chemistry
    Decreased albumin311
    Decreased magnesium272
    Increased creatinine160
    Decreased potassium154

    * The denominator used to calculate the rate varied from 98 to 101 based on the number of patients with a baseline value and at least one post-treatment value.

    Immunogenicity: Anti-Drug Antibody-Associated Adverse Reactions In studies 0416, 0417, 0401, and 0403 in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer who received ELAHERE at 6 mg/kg AIBW administered intravenously once every 3 weeks, 9% (57/626) developed anti-drug antibodies. Infusion reactions (including bronchospasm, erythema, eyelid erythema, flushing, hypersensitivity, periorbital edema, rash, allergic rhinitis, face edema) occurred in 26% (15/57) of patients with anti-drug antibodies and in 7% (41/569) who did not develop anti-drug antibodies [see Clinical Pharmacology (12.6)].

  • 7 DRUG INTERACTIONS

    7.1 Effects of Other Drugs on ELAHERE

    Strong CYP3A4 Inhibitors

    DM4 is a CYP3A4 substrate. Concomitant use of ELAHERE with strong CYP3A4 inhibitors may increase unconjugated DM4 exposure [see Clinical Pharmacology (12.3)], which may increase the risk of ELAHERE adverse reactions [see Adverse Reactions (6)]. Closely monitor patients for adverse reactions with ELAHERE when used concomitantly with strong CYP3A4 inhibitors [see Warnings and Precautions (5)].

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    Based on its mechanism of action, ELAHERE can cause embryo-fetal harm when administered to a pregnant woman because it contains a genotoxic compound (DM4) and affects actively dividing cells [see Clinical Pharmacology (12.1), Nonclinical Toxicology (13.1)]. Human immunoglobulin G (IgG) is known to cross the placental barrier; therefore, ELAHERE has the potential to be transmitted from the mother to the developing fetus. There are no available human data on ELAHERE use in pregnant women to inform a drug-associated risk. No reproductive or developmental animal toxicity studies were conducted with mirvetuximab soravtansine-gynx. Advise patients of the potential risk to a fetus.

    The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

    Data

    Animal Data: No reproductive or developmental animal toxicity studies have been conducted with mirvetuximab soravtansine-gynx. The cytotoxic component of ELAHERE, DM4, disrupts microtubule function, is genotoxic, and can be toxic to actively dividing cells, suggesting it has the potential to cause embryotoxicity and teratogenicity.

    8.2 Lactation

    Risk Summary

    There are no data on the presence of mirvetuximab soravtansine-gynx in human milk or the effects on the breastfed child or milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with ELAHERE and for 1 month after the last dose.

    8.3 Females and Males of Reproductive Potential

    ELAHERE can cause embryo-fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)].

    Pregnancy Testing

    Verify pregnancy status in females of reproductive potential prior to initiating ELAHERE.

    Contraception

    Females: Advise females of reproductive potential to use effective contraception during treatment with ELAHERE and for 7 months after the last dose.

    8.4 Pediatric Use

    Safety and effectiveness of ELAHERE have not been established in pediatric patients.

    8.5 Geriatric Use

    Of the 682 patients with epithelial ovarian cancer who were treated with ELAHERE across studies, 44% of patients were ≥65 years old. Grade ≥3 adverse reactions occurred in 51% of patients ≥65 years and in 45% <65 years. No clinically meaningful differences in efficacy or safety were observed between patients ≥65 years of age compared to younger patients.

    Age does not have a clinically meaningful effect on the pharmacokinetics of ELAHERE [see Clinical Pharmacology (12.3)].

    8.6 Renal Impairment

    No dosage adjustment of ELAHERE is recommended for patients with mild to moderate renal impairment (CLcr 30 to 89 mL/min). The effect of severe renal impairment (CLcr 15 to < 30 mL/min) or end-stage renal disease on ELAHERE is unknown [see Clinical Pharmacology (12.3)].

    8.7 Hepatic Impairment

    Avoid use of ELAHERE in patients with moderate or severe hepatic impairment (total bilirubin >1.5 ULN).

    No dosage adjustment of ELAHERE is recommended for patients with mild hepatic impairment (total bilirubin ≤ULN and AST >ULN or total bilirubin >1 to 1.5 times ULN and any AST) [see Clinical Pharmacology (12.3)].

  • 11 DESCRIPTION

    Mirvetuximab soravtansine-gynx is a folate receptor alpha (FRα)-directed antibody-drug conjugate (ADC) consisting of three components: 1) an anti-FRα monoclonal antibody of IgG1 subtype 2) the small molecule anti-tubulin agent DM4 (a maytansine derivative) and 3) a linker, sulfo-SPDB (1-(2,5-dioxopyrrolidin-1-yl)oxy-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid) that covalently attaches DM4 to the mirvetuximab antibody. Mirvetuximab soravtansine-gynx has an approximate molecular weight of 150 kDa. An average of 3.4 molecules of DM4 are attached to each antibody molecule. Mirvetuximab soravtansine-gynx is produced by chemical conjugation of the antibody and small molecule components. The antibody is produced by mammalian (Chinese hamster ovary) cells, and the small molecule components are produced by chemical synthesis.

    Mirvetuximab soravtansine-gynx has the following structure:

    Mirvetuximab soravtansine-gynx has the following structure:

    ELAHERE (mirvetuximab soravtansine-gynx) injection is supplied as a sterile, preservative-free, clear to slightly opalescent, colorless solution containing 100 mg/20 mL of mirvetuximab soravtansine-gynx in single-dose vials. Each mL of solution contains 5 mg of mirvetuximab soravtansine-gynx, and glacial acetic acid (0.22 mg), polysorbate 20 (0.1 mg), sodium acetate (0.53 mg), sucrose (90 mg), and Water for Injection. The pH is approximately 5.0.

    The ELAHERE vial stoppers are not made with natural rubber latex.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Mirvetuximab soravtansine-gynx is an antibody-drug conjugate (ADC). The antibody is a chimeric IgG1 directed against folate receptor alpha (FRα). The small molecule, DM4, is a microtubule inhibitor attached to the antibody via a cleavable linker. Upon binding to FRα, mirvetuximab soravtansine-gynx is internalized followed by intracellular release of DM4 via proteolytic cleavage. DM4 disrupts the microtubule network within the cell, resulting in cell cycle arrest and apoptotic cell death.

    12.2 Pharmacodynamics

    Exposure-Response Relationships

    Higher exposure to mirvetuximab soravtansine-gynx was associated with higher overall response rates and longer median PFS and OS; higher exposure to mirvetuximab soravtansine-gynx was also associated with higher incidence of ocular adverse reactions as well as marginally increased peripheral neuropathy.

    Cardiac Electrophysiology

    At the approved recommended dose, ELAHERE did not cause large mean increases (>10 msec) in the QTc interval.

    12.3 Pharmacokinetics

    The pharmacokinetics were characterized in patients who received mirvetuximab soravtansine-gynx 0.16 mg/kg to 8.7 mg/kg adjusted ideal body weight (AIBW) (0.03 times to 1.4 times the approved recommended dose of 6 mg/kg AIBW), unless otherwise noted.

    Table 8 summarizes the exposure parameters of mirvetuximab soravtansine-gynx, unconjugated DM4, and its metabolite S-methyl-DM4 following administration after the first cycle (3-weeks). Peak mirvetuximab soravtansine-gynx concentrations were observed near the end of intravenous infusion, while peak unconjugated DM4 concentrations were observed on the second day after administration and the peak S-methyl-DM4 concentrations were observed approximately 3 days after administration. Steady state concentrations of mirvetuximab soravtansine-gynx, DM4, and S-methyl-DM4 were reached after one 3-week cycle. Accumulation of the mirvetuximab soravtansine-gynx, DM4, and S-methyl-DM4 was minimal following multiple cycles.

    Table 8: Exposure Parameters of Mirvetuximab Soravtansine-gynx, Unconjugated DM4, and S-methyl DM4 After First Cycle at a Dosage of 6 mg/kg
    Mirvetuximab Soravtansine-gynx
    Mean (±SD)    		Unconjugated DM4
    Mean (±SD)    		S-methyl-DM4
    Mean (±SD)
    Cmax137.3 (±62.3) µg/mL4.1 (±2.3) ng/mL7.0 (±6.8) ng/mL
    AUCtau20.6 (±6.8) h*mg/mL530 (±245) h*ng/mL1848 (±1585) h*ng/mL

    Cmax = maximum concentration, AUCtau = area under the concentration vs. time curve over the dosing interval (21 days).

    Distribution

    The mean (±SD) steady state volume of distribution of mirvetuximab soravtansine-gynx was 2.6 (±2.9) L.

    Human plasma protein binding of DM4 and S-methyl DM4 was >99%, in vitro.

    Elimination

    For mirvetuximab soravtansine-gynx, total plasma clearance (mean [CV%]) of was 19 mL/hour (52%) and the mean terminal phase half-life after the first dose was 4.8 days leading to a steady state at approximately 24 days.

    For the unconjugated DM4, the total plasma clearance (mean [CV%]) was 14 L/hour (31%) and the mean terminal phase half-life was 2.8 days.

    For S-methyl-DM4, the total plasma clearance (mean [CV%]) was 4.3 L/hour (64%) and the mean terminal phase half-life was 5 days.

    Metabolism

    The monoclonal antibody portion of mirvetuximab soravtansine-gynx is expected to be metabolized into small peptides by catabolic pathways. Unconjugated DM4 and S-methyl-DM4 undergo metabolism by CYP3A4. In human plasma, DM4 and S-methyl DM4 were identified as the main circulating metabolites, accounting for approximately 0.4% and 1.4% of mirvetuximab soravtansine-gynx AUC, respectively.

    Excretion

    S-methyl DM4 and DM4-sulfo-SPDB-lysine were detected in urine within 24 hours of infusion as the main metabolites.

    Specific Populations

    No clinically significant differences in the pharmacokinetics of mirvetuximab soravtansine-gynx were observed based on age (32 to 89 years), race (White, Black, or Asian), body weight (36 to 136 kg), mild hepatic impairment (total bilirubin ≤ULN and any AST >ULN or total bilirubin >1 to 1.5 times ULN and any AST), or mild to moderate renal impairment (CLcr 30 to 89 mL/min).

    The pharmacokinetics of mirvetuximab soravtansine-gynx in patients with moderate to severe hepatic impairment (total bilirubin >1.5 ULN with any AST) or severe renal impairment (CLcr 15 to 30 mL/min) is unknown.

    Drug Interaction Studies

    Clinical Studies and Model Informed Approaches

    No clinical studies to evaluate the drug-drug interaction potential of mirvetuximab soravtansine-gynx were conducted.

    There were no differences in exposure between patients who received concomitant weak or moderate CYP3A4 inhibitors or P-glycoprotein (P-gp) inhibitors and those who did not.

    In Vitro Studies

    Cytochrome P450 (CYP) Enzymes: Unconjugated DM4 is a time-dependent inhibitor of CYP3A4. Unconjugated DM4 and S-methyl DM4 are not inhibitors of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A. DM4 and S-methyl DM4 are not inducers of CYP1A2, CYP2B6, or CYP3A4. 

    Transporter Systems: Unconjugated DM4 and S-methyl DM4 are substrates of P-gp but are not inhibitors of P-gp.

    12.6 Immunogenicity

    The observed incidence of anti-drug antibodies (ADA), including neutralizing antibody, is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of ADAs in the studies described below with the incidence of ADAs to mirvetuximab soravtansine-gynx in other studies.

    With a median treatment duration of 4.4 months in Studies 0416, 0417, 0401, and 0403, in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer who received mirvetuximab soravtansine-gynx at 6 mg/kg AIBW intravenously every 3 weeks, 9% (57/626) of patients developed anti-mirvetuximab soravtansine-gynx antibodies. Neutralizing antibodies were detected in 47% (27/57) of patients who were ADA-positive.

    No clinically meaningful difference was observed in the trough concentrations of mirvetuximab soravtansine-gynx between ADA-positive and ADA-negative patients. Anti-mirvetuximab soravtansine-gynx antibody formation was associated with a higher incidence of infusion-related reactions [see Adverse Reactions (6.1)]. The effect of anti-drug antibodies on effectiveness has not been fully characterized. Based on limited data, the presence of anti-mirvetuximab soravtansine-gynx antibodies may be associated with decreased efficacy in ADA-positive patients when compared to ADA-negative patients.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Carcinogenicity studies have not been conducted with mirvetuximab soravtansine-gynx or DM4.

    DM4 and the metabolite, S-methyl DM4, were clastogenic in the in vivo rat bone marrow micronucleus study. DM4 and S-methyl DM4 were not mutagenic in the bacterial reverse mutation (Ames) assay.

    Fertility studies have not been conducted with mirvetuximab soravtansine-gynx or DM4.

  • 14 CLINICAL STUDIES

    Study 0416

    The efficacy of ELAHERE was evaluated in Study 0416 (MIRASOL, NCT04209855), a multicenter, open-label, active-controlled, randomized, two-arm, trial in patients (n=453) with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Patients were permitted to receive up to three prior lines of systemic therapy. The trial enrolled patients whose tumors were positive for FRα expression as determined by the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. Patients were excluded if they had corneal disorders, ocular conditions requiring ongoing treatment, Grade >1 peripheral neuropathy, or noninfectious interstitial lung disease.

    Patients were randomized (1:1) to receive ELAHERE 6 mg/kg (based on adjusted ideal body weight) as an intravenous infusion every 3 weeks or investigator’s choice of chemotherapy (paclitaxel, pegylated liposomal doxorubicin [PLD], or topotecan) until disease progression or unacceptable toxicity. Tumor response assessments occurred every 6 weeks for the first 36 weeks and every 12 weeks thereafter. Randomization was stratified by the following factors: number of prior lines of therapy (1 vs. 2 vs. 3) and chemotherapy (paclitaxel vs. PLD vs. topotecan) chosen prior to randomization.

    The major efficacy outcome measures were investigator-assessed progression-free survival (PFS), confirmed overall response rate (ORR), and overall survival (OS). PFS and ORR were evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.

    The median age was 63 years (range: 29 to 88); 66% were White, 12% were Asian, 3% were Black or African American, and 18% did not have race reported. Six percent of patients were Hispanic or Latino. Nearly all patients had an ECOG PS of 0 (55%) or 1 (44%). Fourteen percent of patients had received 1 prior line of systemic therapy, 39% of patients had received 2 prior lines of systemic therapy, and 47% of patients had received 3 prior lines of systemic therapy. Thirty-seven percent of patients received prior systemic therapy for platinum-resistant disease. Sixty-two percent of patients received prior bevacizumab and 55% had received a prior PARP inhibitor.

    ELAHERE demonstrated a statistically significant improvement in PFS, ORR, and OS for patients randomized to ELAHERE as compared with chemotherapy.

    Efficacy results for Study 0416 are summarized in Table 9 and Figures 1 and 2.

    Table 9: Efficacy Results in Study 0416
    ELAHERE
    n=227    		Chemotherapy*
    n=226
    Progression-free survival (PFS)
    Number (%) of patients with events176 (78)166 (73)
    Median, months (95% CI)5.6 (4.3, 5.9)4.0 (2.9, 4.5)
    Hazard ratio (95% CI)0.65 (0.52, 0.81)
    p-valuea<0.0001
    Overall Survival (OS)
    Number (%) of patients with events90 (40)114 (50)
    Median, months (95% CI)16.5 (14.5, 24.6)12.7 (10.9, 14.4)
    Hazard Ratio (95% CI)0.67 (0.50, 0.88)
    p-valuea0.0046
    Confirmed overall response rate (ORR)
    Number of patients with measurable disease at baseline225224
    ORR (95% CI)42% (36, 49)16% (12, 22)
    Complete response5%0%
    Partial response37%16%
    p-valueb<0.0001

    * Chemotherapy: paclitaxel, PLD, or topotecan.

    a Two-sided p-value based on stratified log-rank test.

    b Two-sided p-value based upon Cochran-Mantel-Haenszel (CMH) test.

    Figure 1: Kaplan-Meier Curve for Progression-free Survival in Study 0416

    Figure 1: Kaplan-Meier Curve for Progression-free Survival in Study 0416 

    Figure 2: Kaplan-Meier Curve for Overall Survival in Study 0416

    Figure 2: Kaplan-Meier Curve for Overall Survival in Study 0416

    Study 0417

    The efficacy of ELAHERE was evaluated in Study 0417 (SORAYA, NCT04296890), a single-arm trial of patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (n=106). Patients were permitted to receive up to three prior lines of systemic therapy. All patients were required to have received prior bevacizumab. The trial enrolled patients whose tumors were positive for FRα expression as determined by the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. Patients were excluded if they had corneal disorders, ocular conditions requiring ongoing treatment, Grade >1 peripheral neuropathy, or noninfectious interstitial lung disease.

    Patients received ELAHERE 6 mg/kg (based on adjusted ideal body weight) as an intravenous infusion every 3 weeks until disease progression or unacceptable toxicity. Tumor response assessments occurred every 6 weeks for the first 36 weeks and every 12 weeks thereafter.

    The major efficacy outcome measures were investigator-assessed overall response rate (ORR) and duration of response (DOR) evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.

    The efficacy evaluable population included 104 patients with platinum-resistant disease, who had measurable disease, and received at least one dose of ELAHERE. In these 104 patients, the median age was 62 years (range: 35 to 85); 96% were White, 2% were Asian, and 2% did not have race reported. Two percent of patients were Hispanic or Latino. All patients had an ECOG PS of 0 (57%) or 1 (43%). Ten percent of patients had received 1 prior line of systemic therapy, 39% of patients had received 2 prior lines of systemic therapy, and 50% of patients had received 3 prior lines of systemic therapy. All patients had received prior bevacizumab and 47% had received a prior PARP inhibitor.

    Efficacy results for Study 0417 are summarized in Table 10.

    Table 10: Efficacy Results in Study 0417
    ELAHERE
    (N=104)
    Confirmed Overall Response Ratea
    (95% CI)    		32%
    (23, 42)
               Complete response rate5%
               Partial response rate27%
    Duration of ResponseN=33
               Median duration of response, months
               (95% CI)    		6.9
    (5.6, 9.7)

    a Investigator assessment.

    Response assessment results using independent radiology review were consistent with investigator assessment.

  • 15 REFERENCES

    1“OSHA Hazardous Drugs.” OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    How Supplied

    Each ELAHERE (mirvetuximab soravtansine-gynx) injection carton (NDC: 72903-853-01) contains:

    • One single-dose vial containing 100 mg of mirvetuximab soravtansine-gynx in 20 mL (5 mg/mL) of clear to slightly opalescent, colorless sterile solution.

    Storage and Handling

    Store ELAHERE vials upright in a refrigerator at 2°C to 8°C (36°F to 46°F) until the time of preparation in the original carton to protect from light.

    Do not freeze or shake.

    ELAHERE is a hazardous drug. Follow applicable special handling and disposal procedures1.

  • 17 PATIENT COUNSELING INFORMATION

    Advise the patient to read the FDA-approved patient labeling (Medication Guide).

    Ocular Disorders

    Inform patients about the need for eye exams before and during treatment with ELAHERE.

    Advise patients to contact their healthcare provider promptly if they experience any visual changes. Advise patients to use steroid eye drops and artificial tear substitutes [see Dosage and Administration (2.3) and Warnings and Precautions (5.1)].

    Pneumonitis

    Advise patients to immediately report new or worsening respiratory symptoms [see Dosage and Administration (2.3) and Warnings and Precautions (5.2)].

    Embryo-Fetal Toxicity

    Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise female patients to inform their healthcare provider of a known or suspected pregnancy [see Use in Specific Populations (5.4, 8.1, 8.3)].

    Advise females of reproductive potential to use effective contraception during treatment with ELAHERE and for 7 months after the last dose [see Use in Specific Populations (8.1, 8.3)].

    Lactation

    Advise women not to breastfeed during treatment with ELAHERE and for 1 month after the last dose [see Use in Specific Populations (8.2)].

    Manufactured by:
    AbbVie Inc.
    North Chicago, IL 60064, USA 
    U.S. License 1889

    ©2024 AbbVie Inc. All rights reserved.
    ELAHERE and its design are trademarks of ImmunoGen, Inc., an AbbVie company.
    752962 R1

  • MEDICATION GUIDE

    MEDICATION GUIDE
    ELAHERE® (el-ah-HERE)
    (mirvetuximab soravtansine-gynx)
    injection, for intravenous use
    What is the most important information I should know about ELAHERE?
    ELAHERE can cause serious side effects, including:
    • Eye problems. Eye problems are common with ELAHERE and can also be severe. Tell your healthcare provider right away if you develop any eye problems during treatment with ELAHERE, including blurred vision, dry eyes, sensitivity to light, eye pain, eye redness, or new or worsening vision changes.
      • Your healthcare provider will send you to see an eye care professional to check your eyes before you start treatment with ELAHERE, during treatment with ELAHERE, and as needed for any worsening signs and symptoms of eye problems.
      • Your healthcare provider will prescribe steroid eye drops and lubricating eye drops before you start and during your treatment with ELAHERE. You should use eye drops as directed by your healthcare provider.
      • Do not wear contact lenses throughout your treatment with ELAHERE unless you are told to use them by your healthcare provider.
    See “What are the possible side effects of ELAHERE?” for more information about side effects.
    What is ELAHERE?
    ELAHERE is a prescription medicine used to treat adults with folate receptor-alpha positive ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who:
    • have not responded to or are no longer responding to treatment with platinum-based chemotherapy, and
    • have received 1 to 3 prior types of chemotherapy.
    Your healthcare provider will perform a test to make sure that ELAHERE is right for you.
    It is not known if ELAHERE is safe and effective in children.
    Before receiving ELAHERE, tell your healthcare provider about all of your medical conditions, including if you:
    • have vision or eye problems.
    • have numbness or tingling in your hands or feet.
    • have liver problems.
    • are pregnant or plan to become pregnant. ELAHERE can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ELAHERE.
      Patients who are able to become pregnant:
      • Your healthcare provider should do a pregnancy test before you start treatment with ELAHERE.
      • You should use an effective birth control (contraception) during treatment and for 7 months after your last dose of ELAHERE.

    • are breastfeeding or plan to breastfeed. It is not known if ELAHERE passes into your breast milk. Do not breastfeed during treatment and for 1 month after your last dose of ELAHERE.
    Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking certain other medicines during treatment with ELAHERE may cause side effects.
    How will I receive ELAHERE?
    • ELAHERE will be given to you by infusion into your vein (intravenous or IV).
    • Before each dose of ELAHERE you will receive medicines to help prevent infusion related reactions, nausea, and vomiting.
    • ELAHERE is usually given every 3 weeks (21-day cycle). Your healthcare provider will decide how many cycles you need.
    What are the possible side effects of ELAHERE?
    ELAHERE can cause serious side effects, including:
    • See “What is the most important information I should know about ELAHERE?”
    • Lung problems (pneumonitis). ELAHERE can cause severe or life-threatening inflammation of the lungs that may lead to death. Tell your healthcare provider right away if you get new or worsening symptoms, including trouble breathing, shortness of breath, cough, or chest pain.
    • Peripheral neuropathy. Nerve problems called peripheral neuropathy are common with ELAHERE and can also be severe. Your healthcare provider will monitor you for signs and symptoms of nerve problems. Tell your healthcare provider if you get new or worsening numbness, tingling, burning sensation or pain in your hands or feet or muscle weakness.
    The most common side effects and abnormal labs of ELAHERE include:
    • increased liver enzymes in the blood
    • decreased platelets
    • feeling tired
    • decreased magnesium level in the blood
    • blurred vision
    • dry eye
    • nausea
    • constipation
    • diarrhea
    • vomiting
    • stomach-area (abdominal) pain
    • decreased albumin level in the blood
    • changes in the cornea (part of the eye)
    • decreased appetite
    • peripheral neuropathy
    • muscle, bone, or joint pain
    • decreased red or white blood cell counts
    Your healthcare provider may change your dose of ELAHERE, delay treatment, or completely stop treatment if you have certain side effects.
    These are not all of the possible side effects of ELAHERE.
    Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
    General information about the safe and effective use of ELAHERE.
    Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. If you would like more information about ELAHERE, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about ELAHERE that is written for healthcare professionals.
    What are the ingredients in ELAHERE?
    Active ingredient: mirvetuximab soravtansine-gynx
    Inactive ingredients: glacial acetic acid, polysorbate 20, sodium acetate, sucrose, Water for Injection.
    Manufactured by: AbbVie Inc., North Chicago, IL 60064, USA
    U.S. License 1889
    ©2024 AbbVie Inc. All rights reserved.
    ELAHERE and its design are trademarks of ImmunoGen, Inc., an AbbVie company.
     752962 R1
    For more information, go to www.elahere.com or call 1-833-ELAHERE.

    This Medication Guide has been approved by the U.S. Food and Drug Administration.       Revised 10/2024

  • PRINCIPAL DISPLAY PANEL

    NDC: 72903-853-01
    Rx Only
    ELAHERE®
    mirvetuximab soravtansine-gynx
    Injection
    100mg/20ml
    (5mg/ml)
    For Intravenous Infusion after
    Dilution in 5% Dextrose Injection, USP
    Single-dose vial.
    Discard unused portion
    Warning: Hazardous Drug
    Dispence the enclosed
    Medication Guide to each patient.
    abbvie

    NDC: <a href=/NDC/72903-853-01>72903-853-01</a> Rx Only ELAHERE® mirvetuximab soravtansine-gynx Injection 100mg/20ml (5mg/ml) For Intravenous Infusion after Dilution in 5% Dextrose Injection, USP Single-dose vial. Discard unused portion Warning: Hazardous Drug Dispence the enclosed Medication Guide to each patient. abbvie

  • INGREDIENTS AND APPEARANCE
    ELAHERE 
    mirvetuximab soravtansine injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 72903-853
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    MIRVETUXIMAB SORAVTANSINE (UNII: 98DE7VN88D) (MIRVETUXIMAB SORAVTANSINE - UNII:98DE7VN88D) MIRVETUXIMAB SORAVTANSINE5 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    ACETIC ACID (UNII: Q40Q9N063P) 0.22 mg  in 1 mL
    POLYSORBATE 20 (UNII: 7T1F30V5YH) 0.1 mg  in 1 mL
    SODIUM ACETATE (UNII: 4550K0SC9B) 0.53 mg  in 1 mL
    SUCROSE (UNII: C151H8M554) 90 mg  in 1 mL
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 72903-853-011 in 1 CARTON11/14/2022
    120 mL in 1 VIAL, SINGLE-USE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    BLABLA76131011/14/2022
    Labeler - ImmunoGen, Inc. (011991874)

    • Trademark Results [ELAHERE]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    ELAHERE
    ELAHERE
    97693875 not registered Live/Pending
    ImmunoGen, Inc.
    2022-11-28
    ELAHERE
    ELAHERE
    97676672 not registered Live/Pending
    ImmunoGen, Inc.
    2022-11-14
    ELAHERE
    ELAHERE
    97676668 not registered Live/Pending
    ImmunoGen, Inc.
    2022-11-14
    ELAHERE
    ELAHERE
    90488884 not registered Live/Pending
    ImmunoGen, Inc.
    2021-01-26
    ELAHERE
    ELAHERE
    90009729 not registered Live/Pending
    ImmunoGen, Inc.
    2020-06-18
    ELAHERE
    ELAHERE
    88268164 not registered Live/Pending
    ImmunoGen, Inc.
    2019-01-18
    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.